Alterola Biotech, Inc.: 10-Q filed 2022-03-01
What Alterola Biotech, Inc. reported in its quarterly report filed 2022-03-01 (fiscal Q3 2022): 22 published measures, 40 facts as tagged in accession 0001663577-22-000134.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-03-01
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001663577-22-000134 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Alterola Biotech, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 12,090,705 | USD | |
| At 2021-03-31 | 519 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 1,386,849 | USD | |
| At 2021-05-28 | 389,721 | USD | |
| At 2021-03-31 | 759,638 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 10,703,856 | USD | |
| At 2021-03-31 | -759,119 | USD | |
| At 2021-01-06 | 136 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 40,109 | USD | |
| At 2021-03-31 | 519 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | -2,800,677 | USD | 92 |
| 2021-04-01 to 2021-12-31 | -3,213,315 | USD | 275 |
| 2021-01-07 to 2021-03-31 | -343,033 | USD | 84 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-12-31 | -2,596,081 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-12-31 | 14,625,352 | USD | 275 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-12-31 | -12,000,000 | USD | 275 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | -4,712,691 | USD | |
| At 2021-03-31 | -1,499,376 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | -2,800,677 | USD | 92 |
| 2021-04-01 to 2021-12-31 | -3,213,315 | USD | 275 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 90,705 | USD | |
| At 2021-03-31 | 519 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 1,217,811 | USD | |
| At 2021-03-31 | 759,638 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 574,703 | USD | |
| At 2021-03-31 | 98,379 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | 2,800,677 | USD | 92 |
| 2021-04-01 to 2021-12-31 | 3,213,315 | USD | 275 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | 61,999 | USD | 92 |
| 2021-04-01 to 2021-12-31 | 322,324 | USD | 275 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 786,300,000 | shares | |
| At 2021-03-31 | 754,280,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 14,633,951 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 211,750 | USD | |
| At 2021-03-31 | 20,244 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2009-04-16 to 2021-12-31 | -4,712,691 | USD | 4643 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | 50,139 | USD | 92 |
| 2021-04-01 to 2021-12-31 | 54,779 | USD | 275 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-12-31 | -35,802 | USD | 275 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-12-31 | 476,324 | USD | 275 |
Inspect the source
- Entity
- Alterola Biotech, Inc. / CIK 0001442999
- Captured
- 2026-09-21T17:19:50.475Z
- SEC response SHA-256
87a3a16f9156f52960516ff7604a147caa80abebfe964591df0bd913491df844
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001442999.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))